HighTower Advisors LLC Sells 192,349 Shares of Danaher Corporation $DHR

HighTower Advisors LLC cut its stake in shares of Danaher Corporation (NYSE:DHR) by 48.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 201,323 shares of the conglomerate’s stock after selling 192,349 shares during the period. HighTower Advisors LLC’s holdings in Danaher were worth $38,348,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Main Street Group LTD bought a new position in shares of Danaher during the first quarter worth approximately $25,000. N.E.W. Advisory Services LLC bought a new stake in Danaher in the 2nd quarter valued at $25,000. JPL Wealth Management LLC bought a new stake in Danaher in the 3rd quarter valued at $25,000. WFA of San Diego LLC acquired a new position in Danaher in the 2nd quarter valued at $26,000. Finally, Hilton Head Capital Partners LLC bought a new position in Danaher during the 4th quarter worth $27,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 1.2%

Shares of NYSE DHR opened at $205.23 on Wednesday. The stock has a market capitalization of $144.28 billion, a P/E ratio of 36.45, a PEG ratio of 2.59 and a beta of 0.78. The stock’s fifty day moving average is $202.33 and its 200 day moving average is $192.13. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s revenue was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.77 earnings per share. Sell-side analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DHR. Wolfe Research downgraded Danaher from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. Citigroup assumed coverage on shares of Danaher in a research note on Tuesday, May 26th. They issued a “buy” rating and a $230.00 price target on the stock. Stifel Nicolaus lowered their price target on shares of Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research report on Wednesday, July 22nd. HSBC decreased their target price on shares of Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Finally, Piper Sandler started coverage on shares of Danaher in a research report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $228.91.

Danaher Profile

Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.